Blood transfusion suppresses cutaneous cell-mediated immunity

Area of Science:

• Immunology
• Nephrology
• Transplantation Science

Background:

• Cutaneous cell-mediated immunity (CMI) plays a role in immune responses, including allograft rejection.
• Patients with end-stage renal disease (ESRD) undergoing hemodialysis may have altered immune function.
• The dinitrochlorobenzene (DNCB) skin test is a common method to assess CMI.

Purpose of the Study:

• To evaluate DNCB-induced CMI in ESRD patients on hemodialysis and pre-transplant.
• To identify factors influencing CMI in these patients, particularly those related to renal allograft rejection.

Main Methods:

• Dinitrochlorobenzene (DNCB) skin testing was performed on ESRD patients.
• Seven factors (age, sex, blood groups, disease etiology, HLA-DRw6, blood transfusions, dialysis duration) were analyzed for their effect on DNCB response.
• Multiple regression analysis was used to determine the impact of blood transfusions and dialysis duration.

Main Results:

• Twenty-seven percent of patients exhibited suppressed CMI, indicated by a negative DNCB response.
• Blood transfusions and dialysis duration were correlated with decreased DNCB response.
• Multiple regression revealed blood transfusions as a major suppressive factor, with dialysis duration having a minor effect.

Conclusions:

• DNCB-induced CMI partially reflects the general CMI involved in allograft rejection.
• The suppressive effect of blood transfusions on CMI limits the DNCB test's utility in predicting renal allograft rejection.
• Further research may be needed to understand immune modulation in ESRD patients and its impact on transplantation outcomes.